EAU 2017 | What does the earlier application of immune-oncology agents mean for urological cancer teams?

Joaquim Bellmunt, MD, PhD, from the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, discusses the implications of earlier immune-oncology treatments for multidisciplinary teams at the European Association of Urology (EAU) conference 2017 in London, UK. Dr Bellmunt highlights the new results on immune-oncological agents presented at this conference, and that the treatment of urological cancers requires a multidisciplinary team approach.He says it is crucial that the community treating genitourinary patients is aware of the treatment advances, and how to manage these in the setting of earlier treatments.